Second blood pressure medication recalled due to packaging error

Crescent Pharma Limited is recalling a second batch of the blood pressure medicine, ramipril, due to a packaging error at the manufacturing site.

The class 2 recall was announced after a pack of ramipril 10 mg capsules (batch number GR174091) was found to contain one blister pack of ramipril 5 mg capsules (batch number GR164094) inside the sealed carton.

According to the Medicines and Healthcare products Regulatory Agency (MHRA), both product batches are produced by the same manufacturer, at the same site, and the error appears to have occurred during secondary packaging of the cartons of batch GR174091.

The recall is being made as a precautionary measure and applies to all packs of ramipril 10 mg capsule, pack size 28, batch number GR174091.

This recall comes after a Crescent Pharma Limited recalled packs of ramipril 5 mg capsules (batch number GR164099) in March, as they contained blister strips of amlodipine 5 mg tablets inside the sealed carton.

Ramipril is a standard anti-hypertensive drug. Both strengths – 5 mg and 10 mg – of the medication are used to treat high blood pressure, heart failure, and kidney disease. The risk to patients of taking the lower dose of this medicine for a limited time is very low, and any possible impact is expected to be gradual rather than immediate or life threatening.

Healthcare professionals have been advised to stop supplying this batch immediately, to quarantine all remaining stock, and return it to their supplier.

If batch or product traceability information is available, pharmacy professionals and other healthcare professionals involved in dispensing medicinal products should identify and immediately contact all patients who have been dispensed the impacted product and ask them to confirm if they have remaining stock within their possession for return.

If batch or product traceability information is not available, pharmacists should identify all patients dispensed this product between 13 May 2025 and 16 April 2026. Where appropriate and feasible, contact all patients who have been dispensed the impacted product with priority given to those who have been dispensed the product most recently and within the last 28 days.

The majority of this batch was distributed in 2025 and therefore it is expected that many of these packs will have been dispensed to patients and consumed.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.